Specialty drugs have been a major cost driver for years, but 2026 marks a significant shift in both scale and urgency. With GLP‑1 medications expanding into new indications, gene therapies entering the market at record pace, and oncology drugs continuing to rise in both cost and utilization, specialty medications are projected to account for more […]